News: Products

3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.

Read more…

Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed

18 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase 2a clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its Exosome technology.

Read more…

Progression with Fosun Pharma underscores commitment to CTX stroke disability programme

13 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that following on from the original Fosun Pharma (“Fosun”) licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme.

Read more…

11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

Read more…

30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.

Read more…

19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.

Read more…

ReNeuron collaborates with UCL to generate anti-cancer immune cells for cancer therapies

26 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that it has entered a collaboration agreement with University College London (‘UCL’) to conduct research into the generation of immune cells from induced pluripotent stem cells (‘iPSCs’) for anti-cancer cell therapies. ReNeuron will be working alongside Dr Claire Roddie, Associate Professor, UCL Cancer Institute, and the team at the UCL CAR-T cell cancer therapy programme.

Read more…

Oxford University Hospitals NHS Foundation Trust activated as ReNeuron’s first UK study site

18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides a further update on the progress of its Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…

Significantly improved delivery of functional proteins to the brain demonstrated in vivo

Exosomes have potential to transform effective drug delivery for key neurological diseases

11 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron’s novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more…

01 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…